Penem compound containing dihydroimidazole formamido

Abstract

The invention relates to a method for preparing an ertapenem compound shown in general formula (I) which contains glyoxalidine formamido, the ester which is easy to be hydrolyzed, the pharmaceutically acceptable salt, the isomer, the hydrate, the ester or salt hydrate thereof and the compound shown in formula (I); the compounds are used for producing medical active materials, particularly preparing medicines for treating and / or preventing infectious diseases and pharmaceutical combination of the compounds shown in formula (I). Definitions of R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7> and R<8> in the general formula (I) can be seen in the specification.

Description

1. Technical field The present invention relates to penem compounds containing dihydroimidazole carboxamide groups, their easily hydrolyzed esters, their pharmaceutically acceptable salts, their isomers, their hydrates, and hydrates of their esters or salts. The preparation method, the pharmaceutical composition containing these compounds, and the use of these compounds for preparing medicines for treating and / or preventing infectious diseases belong to the field of medical technology. 2. Background technology Carbapenems are new broad-spectrum, enzyme-resistant and highly effective β-lactam antibiotics developed in the 1970s. In 1976, Thiamycin, the first carbapenem antibiotic, was discovered, but it was not used clinically due to its poor chemical stability. Later, the chemical structure modification of thiamycin produced a series of carbapenem derivatives. At present, such drugs that have been marketed include imipenem, panipenem, meropenem, doripenem, biapenem, ertapen...

AI Technical Summary

Problems solved by technology

Due to the continuous increase of bacterial resistance and the limitation of digestive tract absorption due to the abuse of antibiotics, the carbapenems currently on the market can only be administered as injections in clinical practice, and the clinical utilization is not high, and the antibacterial activity against MRSA Weak, can no longer meet clinical needs

Images